ArticleAngewandte Chemie (International ed. in English)2014
An antibody with a variable-region coiled-coil "knob" domain.
Article in Angewandte Chemie (International ed. in English), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Stability convergence in natural antibodies with ultra-long hypervariable loops.Communications biology · 2025Article
- Modular design of bi- and multi-specific knob domain fusions.Frontiers in immunology · 2024Article
- Rational design of humanized antibody inhibitors for cathepsin S.Archives of biochemistry and biophysics · 2024Article
- A Poly-ADP-Ribose Polymer-GCSF Conjugate.Biomacromolecules · 2022Article
- A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.Theranostics · 2022Article
- Long-acting antibody ligand mimetics for HER4-selective agonism.Scientific reports · 2020Article
- Isolation of antigen-specific, disulphide-rich knob domain peptides from bovine antibodies.PLoS biology · 2020Article
- Rational Design of a Humanized Antibody Inhibitor of Cathepsin B.Biochemistry · 2020Article
- Animal protein toxins: origins and therapeutic applications.Biophysics reports · 2018Article
- Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability.Scientific reports · 2017Article
- Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies.Science immunology · 2016Article
- Distinct antibody species: structural differences creating therapeutic opportunities.Current opinion in immunology · 2016Review
- Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry.Analytical chemistry · 2015Article
- Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- HDX-MS guided drug discovery: small molecules and biopharmaceuticals.Current opinion in structural biology · 2014Review
- Influence of domain interactions on conformational mobility of the progesterone receptor detected by hydrogen/deuterium exchange mass spectrometry.Structure (London, England : 1993) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The X-ray crystal structure of a bovine antibody (BLV1H12) revealed a unique structure in its ultralong heavy chain complementarity determining region 3 (CDR3H) that folds into a solvent-exposed β-strand "stalk" fused to a disulfide crosslinked "knob" domain. We have substituted an antiparallel heterodimeric coiled-coil motif for the β-strand stalk in this antibody. The resulting antibody (Ab-coil) expresses in mammalian cells and has a stability similar to that of the parent bovine antibody. MS analysis of H-D exchange supports the coiled-coil structure of the substituted peptides. Substitution of the knob-domain of Ab-coil with bovine granulocyte colony-stimulating factor (bGCSF) results in a stably expressed chimeric antibody, which proliferates mouse NFS-60 cells with a potency comparable to that of bGCSF. This work demonstrates the utility of this novel coiled-coil CDR3 motif as a means for generating stable, potent antibody fusion proteins with useful pharmacological properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.